Answers are grounded in this paper and cite their sources.
Premature ovarian failure (POF), formerly known as premature menopause, is defined as the loss of ovarian function before the age of 40. It is associated with hypoestrogenism and follicle loss, resulting in menstrual irregularity, infertility and reduced quality of life. The main approach in the treatment of this pathology remains the use of hormonal therapy. However, given the side effects inherent in this type of treatment, the use of non-hormonal methods of treatment has attracted increasing attention of researchers in recent years. This review presents the results of studies on laboratory animals aimed at investigating the possibility of using phytopreparations, microRNAs, mitochondrial therapy and stem cell therapy to correct ovarian function. Experience in clinical application of in vitro activation, intraovarian infusion of platelet-rich plasma, immunoglobulins and combined technologies is presented. The aim of the review is to summarise the scientific data presented in the literature studies on the problem of existing non-medication approaches to the therapy of premature ovarian failure, allowing to restore their function.
No takes yet. Share an insight, caveat, or question.
Adamyan et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: